These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 124199)

  • 41. Rats chronically injected with urine from Huntington's chorea patients do not striatal damage.
    Perry TL; Hansen S; Kish SJ; MacLean J; Berry K
    Life Sci; 1981 Jun; 28(25):2869-74. PubMed ID: 6455580
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacological approaches to treatment of hemiballism and hemichorea.
    Becker RE; Lal H
    Brain Res Bull; 1983 Aug; 11(2):187-9. PubMed ID: 6138134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of glutamate decarboxylase in post-mortem brain tissue in Huntington's chorea.
    Iversen LL; Bird ED; Mackay AV; Rayner CN
    J Psychiatr Res; 1974; 11():255-6. PubMed ID: 4282387
    [No Abstract]   [Full Text] [Related]  

  • 44. Uptake and release of GABA and GABA in Huntington's chorea [proceedings].
    Iversen LL
    Psychopharmacol Bull; 1977 Jan; 13(1):30-1. PubMed ID: 138147
    [No Abstract]   [Full Text] [Related]  

  • 45. Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study.
    McGeer PL; McGeer EG; Fibiger HC
    Neurology; 1973 Sep; 23(9):912-7. PubMed ID: 4146891
    [No Abstract]   [Full Text] [Related]  

  • 46. Huntington's Chorea and dimethylaminoethanol (deanol).
    Amsterdam JD; Dubin W
    J Clin Psychiatry; 1978 Jul; 39(7):626-8. PubMed ID: 150413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.
    Finch CE
    Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874
    [No Abstract]   [Full Text] [Related]  

  • 48. [Biochemical aspects of Huntington's disease].
    Bonilla E
    Acta Cient Venez; 1977; 28(6):391-7. PubMed ID: 24971
    [No Abstract]   [Full Text] [Related]  

  • 49. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. THE PNEUMOENCEPHALOGRAM IN HUNTINGTON'S CHOREA.
    BLINDERMAN EE; WEIDNER W; MARKHAM CH
    Neurology; 1964 Jul; 14():601-7. PubMed ID: 14200033
    [No Abstract]   [Full Text] [Related]  

  • 51. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
    Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
    [No Abstract]   [Full Text] [Related]  

  • 52. Huntington's disease: regional alteration in muscarinic cholinergic receptor binding in human brain.
    Wastek GJ; Stern LZ; Johnson PC; Yamamura HI
    Life Sci; 1976 Oct; 19(7):1033-9. PubMed ID: 136582
    [No Abstract]   [Full Text] [Related]  

  • 53. Release of acetylcholine, gamma-aminobutyrate, dopamine and glutamate, and activity of some related enzymes, in rat gustatory neocortex.
    López-García JC; Bermúdez-Rattoni F; Tapia R
    Brain Res; 1990 Jul; 523(1):100-4. PubMed ID: 2207682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of cholinergic agents in Huntington's disease: a reappraisal.
    Nutt JG
    Neurology; 1983 Jul; 33(7):932-5. PubMed ID: 6223236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward an understanding of the pathophysiology of Huntington's chorea.
    Klawans HL; Ilahi MM; Ringel SP
    Confin Neurol; 1971; 33(5):297-303. PubMed ID: 4259526
    [No Abstract]   [Full Text] [Related]  

  • 57. Innervation of hypothalamic and limbic areas by the cholinergic, the GABA-ergic and the catecholaminergic nerve fibers; a quantitative analysis.
    Kataoka K; Sorimachi M; Okuno S; Mizuno N
    Pharmacol Biochem Behav; 1975; 3(1 Suppl):61-73. PubMed ID: 1226400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemical pathology of Huntington's disease.
    Bird ED
    Annu Rev Pharmacol Toxicol; 1980; 20():533-51. PubMed ID: 6446256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.